Anti-inflammatory effect of fullerene C in a mice model of atopic dermatitis by unknown
Shershakova et al. J Nanobiotechnol  (2016) 14:8 
DOI 10.1186/s12951-016-0159-z
RESEARCH
Anti-inflammatory effect of fullerene C60 
in a mice model of atopic dermatitis
Nadezda Shershakova*, Elena Baraboshkina, Sergey Andreev*, Daria Purgina, Irina Struchkova, 
Oleg Kamyshnikov, Alexandra Nikonova and Musa Khaitov
Abstract 
Background:  Water-soluble form of fullerene C60 is a promising tool for the control of ROS-dependent inflammation 
including allergic diseases. Anti-inflammatory effects of C60 (nC60) aqueous dispersion were evaluated in the mouse 
models of atopic dermatitis using subcutaneous (SC) and epicutaneous (EC) applications during 50 days period. A 
highly stable nC60 was prepared by exhaustive dialysis of water-organic C60 solution against water, where the size and 
ζ-potential of fullerene nanoparticles are about 100 nm and −30 mV, respectively.
Results: To induce skin inflammation, female BALB/c mice were EC sensitized with ovalbumin three times during 
one-weekly exposures. The nC60 solution was administrated in mice subcutaneously (SC) (0.1 mg/kg) and epicu-
taneously (EC) (1 mg/kg). Significant suppression of IgE and Th2 cytokines production and a concomitant rise in 
concentrations of Th1 cytokines were observed in nC60-treated groups. In addition, a significant increase in the levels 
of Foxp3+ and filaggrin mRNA expression was observed at EC application. Histological examination of skin samples 
indicated that therapeutic effect was achieved by both EC and SC treatment, but it was more effective with EC. Pro-
nounced reduction of the eosinophil and leukocyte infiltration in treated skin samples was observed.
Conclusions: We suppose that nC60 treatment shifts immune response from Th2 to Th1 and restores to some extent 
the function of the skin barrier. This approach can be a good alternative to the treatment of allergic and other inflam-
matory diseases.
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Background
Atopic dermatitis (AD) is a chronic inflammatory skin 
disease that predominantly affects children and is char-
acterized by skin lesions, persistent erythema, scaling, 
excoriations, and pruritus. In addition, the disease is 
commonly associated with allergic rhinitis and asthma. 
The number of AD patients increased by 10–30 % in chil-
dren and 2–10 % in adults in the last 30 years worldwide 
[1–3]. AD is the result of complex interactions among 
several genetic factors, deficiencies in skin barrier func-
tion, exposure to various allergens and infectious agents 
and features of the immune response [4–6]. In 60  % of 
patients, AD starts before the age of 6 years, in 18 % the 
onset is after the age of 20 [7]. Its pathogenesis involves 
impairments in the skin barrier, allowing abnormally 
enhanced dermal presentation of antigens/allergens to 
the immune system [8, 9]. In many AD patients Th2/IgE-
mediated allergic reactions play leading role, however, 
Th2 cells predominate in the initial stage lesions with a 
switch to Th1-cells in a chronic phase. As a rule, diseases 
arising from a dysfunction of immune cells and/or their 
products often manifest with skin symptoms [10]. Many 
observations suggest that allergic and inflammatory skin 
diseases like AD are mediated by oxidative stress [11–13]. 
Mast cells generate mainly intracellular reactive oxygen 
species (ROS) following the aggregation of FceRI; these 
ROS may act as secondary messengers in the induction 
of several biological responses [14]. A generation of ROS 
induces oxidative protein damage in the stratum cornea, 
which leads to the disruption of barrier function and the 
exacerbation of AD [15, 16].
Open Access
Journal of Nanobiotechnology
*Correspondence:  nn.shershakova@nrcii.ru; sm.andreev@nrcii.ru 
NRC Institute of Immunology FMBA of Russia, Moscow, Russia
Page 2 of 11Shershakova et al. J Nanobiotechnol  (2016) 14:8 
Fullerene is a molecular carbon form with cage sphe-
roid structure, and it possesses strong antioxidant 
activity. At present, the fullerene C60 is produced indus-
trially in large quantities and is commercially available. 
Its unique properties include strong electron-acceptor 
activity, high polarizability and hydrophobicity; a large 
surface of C60 molecule allows attachment of various 
hydrophilic addends, providing prospects for the design 
of new biomedical products. Fullerene and some of its 
derivatives as potent antioxidants (in vitro and in  vivo) 
are capable of effective ROS inactivation [17]. An impor-
tant feature of fullerene C60 is its low toxicity [18, 19], a 
permeability through biological membranes [20, 21], and 
lack of immunogenicity [22]. Thus, fullerene presents a 
promising therapeutic agent for the treatment of aller-
gies and other inflammatory diseases such as Parkinson’s, 
Alzheimer’s and AD.
Anti-inflammatory activity of fullerene derivatives 
was recorded by several investigators, and, in particular, 
researchers from the Luna group (led by Dr. C. L. Kep-
ley) were the pioneers in this field [23–26]. Some C60-
drived compounds were able to inhibit an IgE-dependent 
allergic response. For instance, fullerenol (C60(OH)n) and 
amino-fullerene (C60(NHCH2CH3)n) inhibited in  vitro 
IgE-dependent degranulation of mast cells and secre-
tion of cytokines and prostaglandins in response to aller-
gen and authors suggested that this effect is associated 
with lower levels of ROS in the stimulated cells [23]. On 
the other hand, the C60 aqueous dispersion obtained by 
Andrievsky’s method [27] induced gene expression of 
proinflammatory cytokines (IL-1, TNF-α, IL-6) and Th1 
cytokines (IL-12, IFN-γ) in mice via aerosol administra-
tion to the airways [28]. Aqueous dispersion of C60 (nC60) 
provided inhibitory effect on IgE-mediated histamine 
release from peripheral blood basophils in vitro and sup-
pressed anaphylaxis in mice caused by administration of 
ovalbumin [29]. Similar C60 dispersion exhibited signifi-
cant modulator activity on the DTH reaction suppressing 
Th1 cytokines release [30, 31].
Fullerene C60 in aqueous media always exists in form 
of nanoparticles (clusters), and hence, the degree of their 
possible undesirable effect is still being discussed [32, 33]. 
In several studies, nanoparticles are perceived as toxic 
agents, in others—the damage is not detected. As was 
shown, the polystyrene nanoparticles aggravated AD-
like skin lesions [34] and metal oxide nanoparticles such 
as ZnO induced systemic production of IgE antibodies 
[35]. Currently, nanoparticles were used for transcutane-
ous drugs delivery, but not for the AD therapy [36, 37]. It 
should be noted, that the use of fullerene at the AD has 
not been described.
The purpose of this study was to evaluate the ther-
apeutic properties of the nC60 obtained by novel 
biocompatible method for the treatment of AD induced 
in a mouse model [38].
Results
Aqueous fullerene solution, nC60
Recently, we have proposed a new simple method for 
preparation of C60 aqueous solution using a “dialysis 
principle” [39]. Shortly, the protocol design includes 
the dissolution of crystalline fullerene in N-methylpyr-
rolidone (NMP), dilution of this solution with distilled 
water or aqueous solution of an l-amino acid used as 
a stabilizing agent with subsequent exhaustive dialysis 
against deionized water. Thus, the protocol excludes the 
use of toxic organic solvents (toluene, tetrahydrofuran) 
as well as sonication, heating and durable mixing fre-
quently used in the known methods [27, 40, 41]. This 
approach provides a high conversation of the fuller-
ene C60 from the crystalline state to the solution with 
concentration of C60 up to 1  g/l (at additional vacuum 
concentration) and hydrodynamic size of C60 particles 
about 80–100  nm (Table  1). Absorption spectrum of 
nC60 is characterized by three intense maxima at 219, 
265 and 344 nm and weak broad band between 400 and 
500  nm, and it practically did not differ from those of 
nC60 obtained through other methods. FTIR spectra of 
dried nC60 shows vibration bands of free C60 molecules 
at 1182 and 1428  cm−1 and additional ones at 3500–
3200, 1650–1660, and 1000–1100  cm−1 due to obvi-
ous presence of residual water molecules and NMP (as 
a donor–acceptor complex). Calculations on the molar 
ratio of NMP to fullerene displayed the value 0.7–1.1, 
while a calculation of the ratio H2O to C60 based on the 
hydrogen content gave values from 5 to 10. The NMP is 
known to have low toxicity via oral, dermal and inhala-
tion routes of delivery. In medicine, it has a long track 
recorded as a constituent in medical devices approved 
by the European Commission and FDA and thus can be 
considered as safe [42]. In addition, good heat resistance 
Table 1 Physical parameters of the nC60
s strong, bw broad weak
a With optional vacuum evaporation
Parameter Value
Feasible concentrationa ~1 mg/ml
Average size (nm) 80–100 nm
PDI (polydispersity index) 0.175 ± 5
Zeta potential (mV) –27/30
UV–Vis major absorption peaks (nm) 219 (s), 265 (s), 344 (s), 450 (bw)
FTIR spectra (cm−1) 525, 1000–1100, 1182, 1428, 
1650–1660, 3200–3500
Mol. ratio C60:NMP ~1
Mol. ratio C60:H2O 5–10
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enables to sterilize the C60 solution prior to its adminis-
tration into the body. In this study, concentration of C60 
in the stock nC60 was 120 µg/ml.
nC60 modulates allergen‑specific antibody production
To induce a mouse AD [38, 43, 44], female BALB/c mice 
were EC sensitized by skin application with 100 μg doses 
of OVA in PBS (1 mg/ml) during three one-week expo-
sures with two-week intervals as described in “Materials 
and methods” and showed in Fig.  1 (“AD” group). Mice 
received nC60 by both EC (“nC60 EC”) and SC (“nC60 SC”) 
administration routes in doses 1 mg/kg and 0.1 mg/kg of 
nC60, respectively, between OVA-applications. Control 
group received PBS-application only (“placebo”). Figure 2 
shows that OVA-specific IgE and IgG1 levels in sera 
were elevated in OVA-sensitized mice (“AD” group). The 
main question was whether nC60 treatment could change 
OVA-specific antibody level in OVA-sensitized mice.
To assess the effect of nC60-treatment on specific IgE 
and IgG production sera were collected after 2-nd and 
3-rd sensitizations. As can be seen from Fig.  2a, spe-
cific IgE concentrations in OVA-sensitized mice were 
reduced after nC60 treatment. SC administration of nC60 
had stronger inhibition effect on IgE production com-
pared with the EC one. This tendency was observed both 
after the 2-nd and 3-rd OVA-sensitizations (2 and 3 sens, 
Fig.  2). After the last sensitization the reduction of IgE 
concentration was about 50  % (statistically significant). 
OVA-specific IgG1 and IgG2a levels and IgG1/IgG2a 
ratio as markers for Th2 and Th1 responses [45] were 
measured for each group, and results (Fig.  2b) suggest 
that the nC60 treatment had no statistically significant 
0,1 mg C60 / kg  SC (on days 8, 15, 29, 36)
or
1 mg C60 / kg EC (on days 8, 10, 12,15, 17, 19, 29, 31, 33, 36, 38, 40) Assay: OVA-specific IgE, 
IgG1, IgG2a, cytokines 
and skin biopsy.











1 sens 2 sens 3 sens
Fig. 1 Sensitization protocol and nC60 treatment. Mice were sensitized with OVA (100 µg) or saline applied at 100 µl to a sterile patch. The patch 
was applied for 1 week and then removed. nC60 treatment was done between the applications (sens): SC (0,1 mg nC60/kg) on days 8, 15, 29, 36; EC 
(1 mg nC60/kg) on days 8, 10, 12, 15, 17, 19, 29, 31, 33, 36, 38, 40. The control group (“placebo”) had no any treating
AD nC60EC  nC60 SC  placebo
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Fig. 2 Changes in concentrations of OVA-specific antibodies in sera obtained after treatment with nC60 detected by ELISA. The results are pre-
sented as mean value (mean ± SE, n = 8 for each). AD, OVA-sensitized mice (AD model); nC60 EC, OVA-sensitized mice treated with nC60 by EC; 
nC60 SC, OVA-sensitized mice treated with nC60 by SC; placebo, PBS-sensitized mice. a OVA-specific IgE response, b OVA-specific IgG1/IgG2a ratio 
(*p < 0.05)
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effect on the specific antibody production (although a 
decreasing trend, especially after 3-rd sensitization was 
observed).
Fullerene‑induced cytokine profile alterations
Analysis of cytokine expression was carried out after the 
3-rd sensitization in supernatants of OVA-stimulated 
mouse splenocytes (3 sensitization, Fig. 1). It was shown 
that the nC60 exerts a strong effect as the IL-4 concen-
tration was decreased by 2.5 times compared with “AD” 
group regardless of the route of administration (Fig. 3a). 
The same effect we also observed for IL-5. In this case, a 
slightly stronger effect was observed via EC application 
(Fig. 3b).
Figure 3c shows that the IL-12 concentration was sig-
nificantly higher in group “nC60 EC” and “placebo” com-
pared with “AD” and “nC60 SC” group. IFN-γ expression 
was significantly increased in nC60 group compared with 
“AD” and normal-control (“placebo”) Fig.  3d. Moreo-
ver, the strongest effect was observed after EC/nC60 
treatment.
Foxp3 + regulatory cells (Foxp3 + Tregs) induction
In this study, we have measured the Foxp3 expression in 
OVA-stimulated mouse splenocytes to evaluate the level 
of Foxp3 + Tregs after the nC60 treatment. As we can see 
a significant increase in Foxp3 expression was observed 
in the “nC60 EC” group compared with “AD” and “pla-
cebo” (Fig. 4). The Foxp3 level was only slightly higher in 
group “nC60 SC” than in “AD”.
Analysis of filaggrin expression
We used a quantitative real-time PCR to evaluate the 
effect of nC60 on expression the FLG in AD-induced mice 
(Fig.  5). It was shown that the nC60 potently promoted 
the FLG expression. The most significant increase of FLG 









































































































Fig. 3 The levels of cytokines IL-4 (a), IL-5 (b) and IL-12 (c) in supernatants of OVA-stimulated mouse splenocytes taken after 3-rd sensitization and 
incubated with OVA for 72 h (quantified by ELISA). Relative expression of IFN-γ mRNA (d) in mouse splenocytes taken after 3-rd sensitization and 
incubated with OVA for 72 h (quantified by real-time PCR). The results are presented as a mean concentration (mean ± SE, n = 8 for each). Designa-
tions of columns in the diagram are the same as those in Fig. 2; *p < 0.05
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was observed at EC/nC60 application, in this case, FLG 
expression was increased about 3 times (p < 0.05).
Histological assay
Skin biopsies from sensitized mice were taken after the 
final 3-rd sensitization. Skin sections were stained with 
H&E and examined at 100-fold magnification. The skin 
samples from the “AD” group had dermal and epidermis 
necrosis from severe to medium degree. There were vis-
ible marked epidermis hyperplasia, pronounced diffuse 
mixed leukocyte infiltrates with eosinophils prevalence 
both in dermis and epidermis (Fig. 6a). The cellular infil-
trate consisted of neutrophils, eosinophils, and lym-
phocytes, while the group “placebo” did not present any 
pathologic changes showing almost normal appearance 
(Fig. 6d). The infiltration degree of leukocytes in dermis 
and epidermis were decreased in SC/nC60-treated mice 
(“nC60 SC”) compared with “AD”, however, the eosino-
phils amount was the same as in the “AD” (Fig. 6c). In this 
case, we observed decrease in the epidermis necrosis and 
destructive hemorrhage in derma. There was a moderate 
epidermal hyperkeratosis obviously as a compensatory 
protection mechanism against damage. Figure 6b shows 
that the most pronounced nC60 therapeutic effect was in 
the case of EC nC60-treated mice (“nC60 EC”). The leu-
kocytes infiltration degree and the eosinophils number 
were significantly reduced in “nC60 EC” group compared 
with “AD” and “nC60 SC”. It was shown, that the epider-
mal necrosis, destructive hemorrhage in dermis and 
hyperkeratosis either were absent or were mild.
We evaluated the histologic pictures in semi-quanti-
tative histological index (score) comparing nC60-treated 
and non-treated groups with each other based on the 
microscopic features. Epidermal thickening, epidermal 
necrosis, epidermal hyperkeratosis, dermal and sub-
cutaneous fat necrosis, swelling, hemorrhage, and cell 
infiltration of dermis and subcutaneous fat were the 
main evaluation criteria for the histologic skin lesions 
(Table 2). Each parameter had a degree of manifestation, 
estimated notional value and appropriate score.
Figure 6e shows that the maximum inflammatory index 
was observed in the “AD” (score  =  24) while the “pla-
cebo” shows the value of 4. The inflammatory indexes for 
groups “nC60 EC” and “nC60 SC” were 14 and 18, respec-
tively. Thus, the skin samples histological analysis showed 
that the nC60 therapy improved histological picture 
reducing an allergic inflammation by approximately 42 
and 25 %, respectively for EC and SC applications com-
pared with the untreated mice.
Discussion
The investigation of fullerene C60 biological effects has 
attracted increasing attention in recent years. An impor-
tant issue is that a crystalline fullerene C60 is practically 
insoluble in an aqueous medium without special process-
ing. In this study, an aqueous solution of the fullerene 
was prepared by novel dialysis method [46]. Based on the 
spectral and elemental analyzes, we can speculate that 
process underlying the C60 solubilization can involve a 

































Fig. 4 Foxp3 expression. The specific mRNA in OVA-stimulated 
mouse splenocytes (incubated with OVA for 72 h) were quantified by 
real-time PCR. The results are presented as mean mRNA expression 
(mean ± SE, n = 8 for each). The relative levels of Foxp3 expression 
were calculated by referring to the HPRT (hypoxanthine guanine 
phosphoribosyltransferase) in each sample. AD: AD mouse model; 
nC60 EC: OVA-sensitized mice treated with nC60 EC; nC60 SC: OVA-
sensitized mice treated with nC60 SC; placebo: PBS-sensitized mice 
(*p < 0.05)


































Fig. 5 FLG expression. The specific mRNA in OVA-stimulated mouse 
splenocytes (incubated with OVA for 72 h) were quantified by 
real-time PCR. The results are presented as mean mRNA expression 
(mean ± SE, n = 8 for each). The relative levels of FLG expression 
were calculated by referring to the HPRT (hypoxanthine guanine 
phosphoribosyltransferase) in each sample. AD: AD mouse model; 
nC60 EC: OVA-sensitized mice treated with nC60 EC; nC60 SC: OVA-
sensitized mice treated with nC60 SC (*p < 0.05)
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formation of the C60 molecule complexes or their clusters 
with NMP followed by partial hydroxylation of nanopar-
ticle surface that is capable of stabilizing the nC60 aggre-
gates. Apparently, these aggregates are surrounded by 
firmly bound water envelope; the water is not removed 
on drying under high vacuum. We suppose, that the 
bond between C60 and NMP has definitely non-covalent 
character (donor–acceptor bond) as evidenced by experi-
mental results and theoretical calculations [47]. It should 
be noted that in course of time (>6  months), we have 
observed a decrease in the heterogeneity of nanoparticles 
size, they have become more uniform in size (100  nm). 
Perhaps, it reflects the establishment of a dynamic equi-
librium in a system where a process of fullerene mole-
cules distribution from cluster to cluster takes place.
We suggest that a new method for the nC60 preparing 
as a biocompatible process is potentially very suitable 
for medical use. The relationship between basic phys-
icochemical characteristics and toxic effects (in vivo) 
of nC60 practically have not been covered in scientific 
literature. The relationship between zeta potentials and 
size of functionalized C60 aggregates and their influ-
ence on the toxicity against bacterial cells was recently 
described. It was shown, that an increase of surface 
charge (indifferently, + or −) always leads to a decrease 
in the size of nanoparticles, but the toxicity is always 
associated with positively charged C60 aggregates [48]. 
Nanoparticles in the nC60 always bear a negative charge. 
In other studies, dimensional effects have been shown 
to affect the cytotoxicity of nC60. Authors speculate that 
this effect may be associated with cell-contacting sur-
face of nanoparticles. The size of nanoparticles is nega-
tively correlated with their toxicity [49]. The question 
of C60 water-soluble form toxicity is closely linked to 
the nanoparticle morphology and its surface chemistry, 
which is also determined by the method of its prepara-
tion. The surface of the nC60 particles differs from those 
described in the literature, in view of the presence of 
complexed hydrophilic component, NMP, and partial 
hydroxylation [46]. Our studies on safety of the nC60 
upon acute intravenous administration to BALB/c mice 
demonstrated that no lethal outcomes were observed 
and the body weight was increased in a pattern similar 
to the control group (unpublished observations). Exact 
dose for humans will be defined at the stage of clinical 
trials only.
Some researchers have found that fullerene deriva-
tives, as fullerenol and amino-fullerene, inhibit in  vitro 
the IgE-dependent degranulation of mast cells, secretion 
of Th2 cytokines and prostaglandins in response to an 
allergen stimulation that appears to be, in part, through 
the cellular ROS levels inhibition [23]. Certain fullerene 
derivatives have been able to prevent the development 
of inflammation and edema in mice after administration 
of phorbol-myristate-acetate (PMA) [24]. The inhibition 
has been shown to depend on the structure of addends 
attached to carbon skeleton. For example, fullerene C70, 
containing 4 glycolic acid molecules, noticeably inhib-
ited artificially induced anaphylaxis, and at the same 
time, fullerene with 4 attached inositol molecules showed 
no activity. It was shown that the fullerene material in 
contact with serum medium or in the cells is capable of 
binding to albumin and other proteins, including some 
enzymes. Thus, perhaps it modulates both enzymatic and 
signaling redox processes in the cell, but available data 







































Fig. 6 Histologic features (scale bar 100 μm). a Mice sensitized with OVA and treated with PBS (“AD”); b mice sensitized with OVA and treated with 
nC60 EC (“nC60 EC”); c mice sensitized with OVA and treated with nC60 SC (“C60 SC”); d mice sensitized with PBS (“placebo”); e evaluation of skin 
lesions by summary histological index given in Table 1
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Earlier, based on a DTH mouse model, it was shown 
that the fullerene treatment significantly attenuated the 
footpad inflammation compared with DTH-control and 
switched the cytokine balance towards Th1-dominance 
[50]. Later we have also shown that Th1 cytokines pro-
duction was significantly suppressed, however it was 
intriguing that Th2 cytokines IL-4 and IL-5 were also sig-
nificantly suppressed by a fullerene treatment [31].
These studies were undertaken in order to evaluate 
the OVA-induced Th1 and Th2 cytokine secretion and 
to determine whether the treatment with nC60 can shift 
Th2 to Th1 response and modulate the proinflammatory 
cytokine production. Th2 cells produce IL-4 and IL-5 that 
have a prominent role in immediate-type hypersensitivity 
and apparently are involved in the initial stages of AD.
The level of Th1 cytokines, including IL-12 and IFN-γ 
was also examined. IL-12, key factor of T-cell differ-
entiation into Th1 cells, plays a dominant role in many 
inflammatory diseases like AD and stimulates the IFN-γ 
production [51]. Thus, we demonstrated that therapeutic 
treatment of AD mice with nC60 shifts immune response 
from Th2 to Th1 for example changing the IgG1/IgG2a 
ratio as markers for Th2 and Th1 responses. We do not 
know the exact mechanism, but one can assume that this 
phenomenon is associated with the action of the nC60 on 
a redox homeostasis. ROS and other redox active mole-
cules fulfill key functions in immunity and Th1/Th2 shift 
Table 2 The main assessment criteria for histological skin 
lesions
No. Criterion The degree  
of manifestation
Score




2 Epidermal necrosis Absent 0
Present 1
3 Epidermal hyperkeratosis Absent 0
Present 1






5 Dermal necrosis Absent 0
Present 1
6 Dermal swelling Absent 0
Present 1
7 Dermal hemorrhage Absent 0
Present 1






9 Subcutaneous fat necrosis Absent 0
Present 1
10 Subcutaneous fat swelling Absent 0
Present 1
11 Subcutaneous fat hemorrhage Absent 0
Present 1
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which appears to be crucially dependent on the activa-
tion of redox-sensitive signaling cascades [52].
Immune regulation and tolerance are essential func-
tions of the immune system to prevent and limit harmful 
immune responses to self- and non-self-antigens. CD4/
CD25 regulatory T cells (Tregs) [53] represent a unique 
lineage of immunoregulatory cells in both humans 
and animals and play a central role in the maintenance 
of immunologic self-tolerance and are involved in the 
release of anti-inflammatory cytokine IL-10 [54]. Lack of 
Foxp3 + CD4+CD25+ T cells leads to immune dysregula-
tion and affected patients often have AD-like skin lesions, 
increased IgE levels, and enhanced Th2 responses. How-
ever, conflicting results regarding the numbers and 
functions of Tregs in AD have been reported. Some inves-
tigators [55] demonstrated the absence of Foxp3 + Tregs 
in patient’s skin that suggests a disregulation in process 
of inflammation. In contrast, other authors [56] showed 
the elevated number of circulating CD4+CD25+ Tregs 
with a normal suppressive function in patients with AD. 
However, they used the CD25 molecule expression only 
(without Foxp3) as a marker for Tregs.
This experiment clearly shows that the EC treatment by 
fullerene leads to increased expression of Foxp3 and may 
shed light on the mechanism of nC60 therapeutic effect.
The weakening of the skin barrier function in patients 
with mutations in filaggrin gene (FLG) probably pro-
motes increased penetration of allergens by transdermal 
route. There is a direct interrelation between the AD 
and nonsense mutations in a filaggrin encoding gene [3]. 
Hence, one of possible therapeutic strategy to regulate 
AD is upregulating the FLG expression [57]. Recently, 
Otsuka et al. have screened more than 1000 compounds 
in a bioactive chemical library to find candidates to 
stimulate FLG mRNA expression and have revealed the 
compound JTC801 promoted the FLG mRNA and pro-
tein expression in  vitro and in  vivo. Potential utility of 
such therapy is indicated by the fact that a modest 20 % 
increase in filaggrin copy number leads to the 40  % 
reduction in AD susceptibility [25, 58].
Based on histological data and the cytokine secretion 
profile switch from Th2 to Th1 pattern we can conclude 
that fullerene nC60 has significant anti-allergic and anti-
inflammatory activity. We observed a significant suppres-
sion of IgE and Th2 cytokines (IL-4 and IL-5) production, 
and with a concomitant increase of Th1 cytokines pro-
duction: IL-12 (at EC application only) and IFN-γ. How-
ever, there was a difference in nC60 effect depended on 
the administration route. More intense specific IgE and 
Th2 cytokines suppression were observed at the EC 
application. In addition, this treatment significantly 
increased the IL-12 level compared with “AD”. Based on 
this facts, we can hypothesize that nC60 reduces AD 
inflammation by activating the IFN-γ production and 
Th2 response suppression [58]. These results suggest that 
nC60 might be used as an agent to suppress proinflamma-
tory cytokine production.
Since AD is a chronic disease, apparently the bar-
rier dysfunction is a leading primary cause of AD. Sur-
prisingly, it turned out that the nC60 quite markedly 
increases the filaggrin expression in  vivo (Fig.  5). We 
could not find any scientific publications on the effect 
of fullerene on filaggrin gene activation except the data 
from presentation of “Vitamin C60 BioResearch Cor-
poration”, where C60/PVP complex (“Radical Sponge”) 
increased FLG expression in RS-treated cells control 
cells about a four times (http://www.novac60.com/wp-
content/uploads/2013/10/VC60-Fullerene-skin-barrier-
effect.pdf ). However, these data once again point out the 
potential of fullerene C60 as a stimulator of the filaggrin 
production.
Histological analysis revealed that positive therapeutic 
effect was achieved both at EC and SC nC60-treatment, 
but the former was more effective. The main dermal 
inflammatory response component was an eosinophilic 
infiltration and a pronounced reduction of eosinophils 
number was observed in “nC60 EC” group. It should be 
noted that this result correlated with the decrease in the 
IL-5 concentration in the same group combined with the 
regenerative processes in the skin as opposed to “AD”.
Thus, in this study we have demonstrated that nC60 
application inhibits the inflammatory process and may 
represent a perspective therapeutic approach to con-
trol allergic inflammation. However further studies are 
needed to understand the mechanism of fullerene activity.
Conclusions
We have found that the nC60 inhibits significantly specific 
IgE production in mouse AD model. In addition, it was 
shown that IL-4, IL-5 levels were significantly decreased 
after EC and SC C60-treatment. It was observed that EC 
C60-treatment shifts immune response from Th2 to Th1, 
markedly increasing the production of IL-12 and IFN-γ. 
We have also revealed that the use of nC60 in EC route 
increases Foxp3 and FLG expression. Thus, simultaneous 
increase of Foxp3 and filaggrin expression leads to reduc-
tion in AD susceptibility. The histological analysis of skin 
samples showed that the nC60 therapy improved histo-
logical picture reducing an allergic inflammation via EC 
as well as SC applications compared with the untreated 
mice. We do not know exactly why EC application is 
more effective then SC one. The possible explanation 
is that EC application with nC60 increases the fullerene 
availability to the immune system due to the presence of 
a large amounts of immune cells in the skin with allergic 
inflammation (AD).
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Thus, the use of nC60 in form of EC application is a 
promising alternative therapeutic approach to control 
allergy inflammation. Exact dose for humans will be 
defined at the stage of clinical trials only.
Methods
Reagents
Ovalbumin (OVA) (Grade V, 99  %) and l-alanine were 
purchased from Sigma-Aldrich (USA). N-methylpyrro-
lidone (NMP, 99 %) was from Panreac (Spain). Crystalline 
fullerene C60 was purchased from SES Research (99.9 %, 
catalog 600–9969, USA).
nC60 preparation
Aqueous fullerene dispersion, nC60, was obtained by 
method described earlier [39]. Briefly, 20 mg of C60 were 
dissolved in 25 ml of N-methylpyrrolidone (magnetic stir-
rer) and resulting dark brown-purple solution was mixed 
with solution of 40 mg l-alanine in 100 ml of deionized 
water. The obtained dark-red transparent solution was 
stirred for 1  h and then subjected to exhaustive dialysis 
(cut off 10/50  kDa) against deionized water. Final dialy-
sis solution was filtered through 0.45  mm nitrocellulose 
membrane resulting in a clear transparent solution with 
brownish-yellow color with concentration 120 µg/ml.
Mice sensitization (AD model) and nC60 treatment
Female BALB/c mice ages 4–6  weeks were purchased 
from the animal nursery Filial SCBMT “Stolbovaya” 
(Moscow region, Russia) and kept in a pathogen-free 
environment with an OVA-free diet. All experimen-
tal procedures were carried out according to order no. 
708 of the Ministry of Health of the Russian Federation 
and “Regulations on the ethical attitudes to laboratory 
animals NRC Institute of Immunology FMBA of Russia 
(Moscow, Russia)”.
EC sensitization of mice to induce a skin inflamma-
tion was carried out as described by Spergel et al. (1998). 
Briefly, mice were shaved with an electric razor. OVA 
(100  µg) in PBS (100  µl) or PBS as placebo was placed 
on a 1 ×  1  cm2 patch of sterile gauze, which was then 
secured onto the skin with a transparent bioclusive dress-
ing (Systagenix Wound Management Limited, United 
Kingdom). The patch was applied thrice over a 1-week 
period. An inspection at the end of each sensitization 
period confirmed that the patch remained in place. C60 
treatment was carried out by subcutaneous (SC; 0.1 mg/
kg) and epicutaneous nC60 (EC; 1  mg/kg) administra-
tions, between OVA-applications as shown in Fig. 1.
Antibody and cytokine assay
The anti-OVA IgE, IgG1, and IgG2a antibodies levels in 
sera obtained before, during, and after nC60-treatment 
were detected by ELISA (ELISA kits from BD, USA) 
according to the manufacturer’s protocol. OVA was used 
for coating the plates. Mouse anti-ovalbumin IgE mAb 
(AbD Serotec, UK) and biotin rat anti-mouse IgE (BD) 
were used for detection anti-OVA mouse IgE. These 
components were used to construct the calibration curve 
and then to analyze sera.
The spleens were taken after the last allergen applica-
tion, and levels of IL-4, IL-5, and IL-12 (p40) in super-
natants of OVA-stimulated splenocytes were determined 
by using ELISA [Duo-Set from R&D Systems (UK) and 
ELISA set from BD (USA)] according to the manufactur-
er’s protocol.
Real‑time PCR
The total RNA from OVA-stimulated mice spleno-
cytes was extracted using the RNeasy Mini Kit (Qiagen, 
Courtaboeuf, France) according to the manufacturer’s 
instructions. The RNA concentration was determined, 
and cDNA was synthesized through a reverse transcrip-
tion reaction (“Reverta-L”, Interlabservice, Russia). Quan-
titative real-time PCR analysis of mRNA expression was 
done by the iQ5 system (Bio-Rad, USA) and the PCR-
Mix kit (Sintol, Russia).
The results are presented as mRNA expression (Foxp3, 
FLG). Calculations to determine the relative level of gene 
expression were made using the comparative Ct method 
(ΔΔCt) referring to the mHPRT in each sample; the 
results are presented as arbitrary units.
Histological analysis
The skin specimens from patch areas were removed for 
histologic examination immediately after the last EC 
application with OVA. Skin biopsies were taken from 
similar body sites, fixed overnight with 10 % paraformal-
dehyde at 4 °C, and embedded in paraffin. Four-microm-
eter sections were stained with hematoxylin and eosin 
(H&E). The histological preparations were analyzed 
under a light microscope (Leica DM2000, Germany) with 
50×, 100×, and 400× lenses.
Statistical analysis
The data are shown as mean ± SE. Statistical analysis was 
done with the program Statistica 8.0 (StatSoft Inc., USA). 
The significance of the results was determined by using 
Student’s t test. Differences were considered significant at 
p < 0.05. The Quantitative RT-PCR data were calculated 
by using the comparative Ct method (ΔΔCt).
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